Logo

Regulus IDs miRNA Target in GSK Collaboration

Jul 21, 2011
Premium

Regulus Therapeutics said this week that it has identified a third, undisclosed microRNA target under its ongoing collaboration with GlaxoSmithKline.

The discovery triggers a preclinical milestone payment of an undisclosed amount, Regulus said.

The companies began working together in 2008, and expanded their alliance in 2010 (GSN 2/25/2010).

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
milestone payments
RNAi
miRNA
Regulus
GSK
Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.